
ALT Figure: Overall survival in the full analysis set. Kaplan–Meier estimates of overall survival in the two groups (A) and subgroup analysis of overall survival in key prespecified subgroups (B). ECOG=Eastern Cooperative Oncology Group. HR=hazard ratio. NE=not evaluable. PD-L1=programmed death-ligand 1. TPS=tumour proportion score. *If the number of events at a subgroup level is less than ten, the median overall survival and corresponding HR (95% CI) are not provided.

ALT Figure: Progression-free survival as assessed by blinded independent central review.\n\n(A) Kaplan\u2013Meier estimates of progression-free survival as assessed by blinded independent central review. (B) Forest plot of progression-free survival in subgroups. One patient with thymoma was excluded from the pembrolizumab group in the subgroup analysis of histologic type. Subgroup analyses will not be presented for any subgroup variable in which one or more levels account for less than 10% of the total analysis population. Confidence intervals have not been adjusted for multiplicity and should not be used to infer statistical significance. Sac-TMT=sacituzumab tirumotecan. PD-L1=programmed death ligand 1. TPS=tumour proportion score. NR=not reached. NE=not estimable.




































